Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2007 Springer Science+Business Media, LLC. All rights reserved. Many lysosomal storage disorders (LSDs) produce neurodegeneration as a prominent feature (Neufeld, 1991). LSDs are autosomal recessive metabolic diseases caused by deficiencies of specific acid hydrolases resulting in accumulation of unmetabolized substrates and macromolecules in lysosomes. There are ∼50 diseases that can be classified as LSDs. The precise mechanisms underlying the actual neurodegenerative process remain to be determined, however, it is known that replacement of the absent gene product typically restores normal metabolism to a cell including forestalling neural cell dysfunction, at least in vitro. Nevertheless, there are currently no effective treatments for the neurological manifestations of the infantile-onset forms of the LSDs. The neuropathology of LSDs is characterized not by discrete focal neuropathology, as in Parkinson's disease, but rather by extensive, multifocal, or even global neural degeneration or dysfunction. Therapy may require not only therapeutic molecules, such as enzymes, but also widespread neural cell replacement.

Original publication

DOI

10.1007/978-0-387-70909-3_14

Type

Chapter

Book title

Lysosomal Storage Disorders

Publication Date

01/01/2007

Pages

197 - 216